COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02587962
Recruitment Status : Terminated (Based on the outcome of a futility analysis on the MSS CRC cohort, the DMC recommended to suspend enrollment in the study based on the absence of responders.)
First Posted : October 27, 2015
Last Update Posted : March 4, 2020
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : February 17, 2020
Actual Study Completion Date : February 17, 2020